Альманах клинической медицины. 2013; : 37-40
ЛАДОННО-ПОДОШВЕННАЯ ЭРИТРОДИЗЕСТЕЗИЯ – СЕРЬЕЗНОЕ ОСЛОЖНЕНИЕ ПРИ ПРИМЕНЕНИИ КАПЕЦИТАБИНА (СОБСТВЕННЫЙ ОПЫТ)
https://doi.org/10.18786/2072-0505-2013-28-37-40Аннотация
Некоторые препараты, применяемые при химиотерапии у больных со злокачественными новообразованиями, наряду с определенной эффективностью обладают способностью вызывать ряд побочных явлений. В частности, при применении капецитабина возможно развитие грозного осложнения – ладонно-подошвенной (палмарно-плантарной) эритродизестезии. В статье приведено собственное наблюдение этого осложнения.
Список литературы
1. Поддубная И.В., Орел Н.Ф. Побочные реакции и осложнения противоопухолевой лекарственной терапии: Руководство по химиотерапии опухолевых заболеваний / под ред. Н.И. Переводчиковой. М.: Практ. мед. 2011. С.441-443.
2. Amado R.G., Wolf M., Peeters M. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer // J. Clin. Oncol. 2008. V.26, No.10. P.1626-1634.
3. Fischel J.L., Formento P., Ciccolini J. et al. Lack of contribution of dihydrofluoro-beta-alanine to the cytotoxicity of 5-deoxy-5-fluorouridine on human keratinocytes // Anti-canc. Drugs. 2004. V.15, No.10. P.969-974.
4. Goldberg R.M. Advances in the treatment of metastatic colorectal cancer // Oncologist. 2005. V.10, No.3. P.40-48.
5. Kohne С.H., Wils J., Lorenz M. et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952 // J. Clin. Oncol. 2003. V.21, No.20. P.3721-3728.
6. Lyass O., Hubert A., Gabizon A.A. Phase I study of doxilcisplatin combination chemotherapy in patients with advanced malignancies // Clin. Cancer Res. 2001. V.7, No.10. P.3040-3046.
7. Nagore E., Insa A., Sanmartin O. et al. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (hand-foot) syndrome: Incidence, recognition and management // Am. J. Clin. Dermatol. 2000. No.1. P.225-234.
8. Rose P.G. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer // Oncologist. 2005. V.10, No.3. P.205-214.
9. Schwartz P.M., Milstone L.M. Thymidine phosphorylase in human epidermal keratinocytes // Biochem. Pharmacol. 1988. V.37, No.2. P.353-355.
10. Smith I.E., A’Hern R.P., Coombes G.A. et al. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neoadjuvant treatment of early breast cancer: 5 year results of the TOPIC trial // Ann. Oncol. 2004. V.15, No.5. P.751-758.
11. Sun W., Haller D.G. Adjuvant therapy for colon cancer // Curr. Oncol. Rep. 2005. V.7, No.3. P.181-185.
12. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer // J. Clin. Oncol. 1998. V.16, No.11. P.3537-3541.
13. Twelves C., Wong A., Nowacki M.P. et al. Capecitabine as adjuvant treatment for stage III colon cancer // N. Engl. J. Med. 2005. V.352, No.26. Р.2696-2704.
14. Zuehlke R.L. Erythematous eruption of the palms and soles associated with mitotane therapy // Dermatologica. 1974. V.148, No.2. P.90-92.
Almanac of Clinical Medicine. 2013; : 37-40
PALMAR-AND-PLANTAR ERYTHRODYSESTHESIA IS A SERIOUS COMPLICATION AFTER CAPECYTABIN: OUR OWN EXPERIENCE
https://doi.org/10.18786/2072-0505-2013-28-37-40Abstract
Some drugs used in chemotherapy of patients with malignant tumors, together with the definite efficiency, is capable of inducing some side effects. In particular, while using capecytabin, development of severe complication – palmar-plantar erythrodysesthesia – is quite possible. Our own observation of this complication is presented in the article.
References
1. Poddubnaya I.V., Orel N.F. Pobochnye reaktsii i oslozhneniya protivoopukholevoi lekarstvennoi terapii: Rukovodstvo po khimioterapii opukholevykh zabolevanii / pod red. N.I. Perevodchikovoi. M.: Prakt. med. 2011. S.441-443.
2. Amado R.G., Wolf M., Peeters M. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer // J. Clin. Oncol. 2008. V.26, No.10. P.1626-1634.
3. Fischel J.L., Formento P., Ciccolini J. et al. Lack of contribution of dihydrofluoro-beta-alanine to the cytotoxicity of 5-deoxy-5-fluorouridine on human keratinocytes // Anti-canc. Drugs. 2004. V.15, No.10. P.969-974.
4. Goldberg R.M. Advances in the treatment of metastatic colorectal cancer // Oncologist. 2005. V.10, No.3. P.40-48.
5. Kohne S.H., Wils J., Lorenz M. et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952 // J. Clin. Oncol. 2003. V.21, No.20. P.3721-3728.
6. Lyass O., Hubert A., Gabizon A.A. Phase I study of doxilcisplatin combination chemotherapy in patients with advanced malignancies // Clin. Cancer Res. 2001. V.7, No.10. P.3040-3046.
7. Nagore E., Insa A., Sanmartin O. et al. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (hand-foot) syndrome: Incidence, recognition and management // Am. J. Clin. Dermatol. 2000. No.1. P.225-234.
8. Rose P.G. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer // Oncologist. 2005. V.10, No.3. P.205-214.
9. Schwartz P.M., Milstone L.M. Thymidine phosphorylase in human epidermal keratinocytes // Biochem. Pharmacol. 1988. V.37, No.2. P.353-355.
10. Smith I.E., A’Hern R.P., Coombes G.A. et al. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neoadjuvant treatment of early breast cancer: 5 year results of the TOPIC trial // Ann. Oncol. 2004. V.15, No.5. P.751-758.
11. Sun W., Haller D.G. Adjuvant therapy for colon cancer // Curr. Oncol. Rep. 2005. V.7, No.3. P.181-185.
12. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer // J. Clin. Oncol. 1998. V.16, No.11. P.3537-3541.
13. Twelves C., Wong A., Nowacki M.P. et al. Capecitabine as adjuvant treatment for stage III colon cancer // N. Engl. J. Med. 2005. V.352, No.26. R.2696-2704.
14. Zuehlke R.L. Erythematous eruption of the palms and soles associated with mitotane therapy // Dermatologica. 1974. V.148, No.2. P.90-92.
